COTA provides oncology research and development, regulatory, commercial, and HEOR teams with detailed real-world patient data to discover new treatment protocols and transform cancer care.
Real, longitudinal patient data across dozens of patient subgroups and oncology disease areas help pharmaceutical and biotech companies optimize their research, development, and commercialization strategies.
COTA data includes over 2M+ patients across a variety of cancer diagnoses, treatment settings, and demographics and is regularly maintained and updated to ensure quality, accuracy, relevance, and linkability.
Get access to a massive database of longitudinal real-world outcomes datasets curated to specific cancer types, subpopulations, or broad population research.
Get expert clinical insights, study design support, and statistical analysis.
Explore our collection of clinical research, recent press, podcasts, and more.
At COTA, we believe the future of healthcare is shaped not only by innovation and data but by people. Each summer, we’re excited to welcome a group of bright, driven interns who bring fresh…
As incidence rates for many common cancers continue to rise – breast, prostate, colorectal, pancreatic, and others – life sciences teams need high-quality cancer real-world data (RWD) to power their research and help develop…
Four Ways Pharmaceutical Companies Are De-Risking R&D with Real-World Data Pharmaceutical research and development is inherently complex and high-risk. Sponsors must ensure that investigational products demonstrate both strong therapeutic efficacy and an acceptable safety…
Partner with COTA for the highest-quality curated cancer patient datasets.
